文献速递眼底病与葡萄膜炎

抗Semaphorin 3A中和抗体在雄性实验性视网膜静脉阻塞小鼠模型中的疗效

Efficacy of an Anti-Semaphorin 3A Neutralizing Antibody in a Male Experimental Retinal Vein Occlusion Mouse Model.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2022-01-01

本研究在视网膜静脉阻塞(RVO)小鼠模型中探究Sema3A中和抗体BI-X单用或联合抗VEGF药物阿柏西普的疗效。结果显示,RVO诱导后视网膜Sema3A表达显著升高,尤其在内核层;BI-X单用及联合治疗均对眼内水肿和视网膜血流有益,且BI-X单药使TNF-α和semaphorin相关蛋白表达变化正常化。结论支持靶向Sema3A治疗眼内水肿和视网膜缺血。

要点

  • RVO小鼠模型中视网膜Sema3A表达显著升高,尤其在内核层。
  • BI-X单用或联合阿柏西普对眼内水肿和视网膜血流均有益。
  • BI-X单药使TNF-α及semaphorin相关蛋白表达变化正常化。

核心结论

  • 研究结果支持靶向Sema3A以治疗眼内水肿和视网膜缺血。

研究设计与样本

  • 在RVO小鼠模型中,于诱导后1天评估对眼内水肿发生的作用、于诱导后7天评估保护作用,并检测视网膜Sema3A表达变化。
  • 通过Western blotting分析治疗后视网膜TNF-α及semaphorin相关蛋白(neuropilin-1和plexin A1)表达变化。
  • 采用视网膜水肿、血流和内核层变薄指标评估BI-X和/或阿柏西普的效果。

主要发现

  • RVO小鼠模型诱导静脉阻塞后视网膜Sema3A表达显著增加,尤其在内核层。
  • BI-X单药治疗及联合抗VEGF治疗均有效,对眼内水肿和视网膜血流显示有益作用。
  • 在RVO小鼠模型中,BI-X单药治疗使TNF-α和semaphorin相关蛋白表达变化正常化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Semaphorin 3A (Sema3A) is a promising therapeutic target for macular edema in age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion (RVO). Anti-vascular endothelial growth factors (anti-VEGFs) are the current standard of care for many retinal diseases. This study investigated the Sema3A neutralizing antibody BI-X and/or anti-VEGF therapy (aflibercept) in an RVO mouse model. Treatment efficacy was examined and grouped by timing subsequent to the RVO mouse model induction: efficacy against the onset of intraretinal edema 1 day postinduction and protective effects at 7 days postinduction. METHODS: We examined the changes in expression of Sema3A in the retina of an RVO mouse model. In addition, changes in expression of tumor necrosis factor (TNF)-α and semaphorin-related proteins (neuropilin-1 and plexin A1) in the retina upon treatment were analyzed by Western blotting. The effects of BI-X and/or aflibercept were evaluated using measures of retinal edema, blood flow, and thinning of the inner nuclear layer. RESULTS: Induction of vein occlusion in the RVO mouse model significantly increased Sema3A expression in the retina, particularly in the inner nuclear layer. BI-X was effective as a monotherapy and in combination with anti-VEGF therapy, demonstrating a beneficial effect on intraretinal edema and retinal blood flow. Moreover, in the RVO mouse model, BI-X monotherapy normalized the changes in expression of TNF-α and semaphorin-related proteins. CONCLUSIONS: These findings support targeting Sema3A to treat intraretinal edema and retinal ischemia.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Nakamura S, Nishinaka A, Hidaka Y, et al. Efficacy of an Anti-Semaphorin 3A Neutralizing Antibody in a Male Experimental Retinal Vein Occlusion Mouse Model. Invest Ophthalmol Vis Sci. 2022. PMID: 35822950. doi:10.1167/iovs.63.8.14

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。